BioMedicure is an emerging, research-driven biopharmaceutical company dedicated to developing, and producing next generation of products to transform cancer research, prevention, control and treatment for eventual cure.

The first series of next generation of products for basic cancer research are enriched cancer stem cells or CancerStemCell™ that are a combination of cancer stem cells obtained by various processes in which non-cancer stem cells are inactivated and cancer stem cells are expanded.

• An enriched cancer stem cells product consists of all enriched cancer stem cells from the same cancer disease type of the same species, such as mouse melanoma CancerStemCell™, useful for cancer cell specific in vitro and in vivo studies where solid-tumor mutations, or antigens in the tumor make a significant difference.
• These enriched cancer stem cells are tumorigenic, heterogeneous, and randomly mutating.
• Enriched cancer stem cells can grow "soild-tumor" in vitro without the aid of matrix gel or growth factor supplement.
• These enriched cancer stem cells have more mutations and antigens than corresponding cancer cell lines, primary tumors, secondary tumors, and metastasized tumors of the same disease.

When the enriched cancer stem cells are treated with Tumorase™, a next generation biochemotherapy agent, a series of CancerVaccine™ products are produced. CancerVaccine™ are a series of whole-cell allogeneic cancer vaccines.

• A CancerVaccine™ product consists of harmless giant liposomes with the cancer cell membrane serving as liposome membrane without extracellular proteins and less cell membrane proteins since they were digested by Tumorase™ .
• A CancerVaccine™ product's liposomes preserve intracellular antigens including mutant proteins, RNAs and DNAs and metabolites and various epigenomic changed lipo-proteins, phosphorylated proteins, carboxylated proteins, methylated proteins and modified glycosylated proteins.
• A CancerVaccine™ product's liposomes preserve all antigens from different cancer cells including various pre-cancer cells, various mature cancer cells, various cancer stem cells and various metastasized cancer cells of the same cancer type.
• When the cancer vaccine is used to vaccinate the same species (such as mouse melanoma cancer vaccine used to vaccinate mouse), the cancer vaccine greatly enhances antigen presentation processes since there is no self-recognition molecular patterns on the membrane of liposomes. One liposome serves as one unit for a macrophage or dendritic cell to engulf. The whole population of various liposomes represents antigens from the heterogeneous population of cancer cells.
• Antigens are sorted out by the potent immune system (including T-helper cells).
• The same antigen is confirmed by other forms, such as DNA, RNA and protein.
• Antigens are remembered by the immune system (i. e. B-cells) by specific DNA sequences.
• Cancer cell specific polyclonal antibodies are produced and coordinated synergistically by the immune system's antigen presentation processes and vaccinations.
• Coordinated immune responses are launched against cancer cells specifically with the participation of various immune components including cancer cell specific polyclonal antibodies, macrophages, dendritic cells, T-cells, natural killer cells and various interleukins and cytokines.

Cancer cell specific polyclonal antibodies are the third series of next generation of products in AntiCancerBody™ that may be useful for cancer patients to fight against cancer with impaired immune systems. In these cases, AntiCancerBody™ immunotherapy may kill metastasized cancer cells, cancer stem cells, and pre-cancer cells. However, since AntiCancerBody™ immunotherapy is not built in DNA, continual supply of the AntiCancerBody™ is needed to kill all cancer cells until the immune system is repaired. Advantages of AntiCancerBody™ over monoclonal antibody are:

• Targeting more cancer cell specific antigens.
• Killing more cancer cell types, including cancer stem cells.
• More effective and efficient since AntiCancerBody™ is the natural way built in the immune system originally.
• Less toxic.

The next generation of products in AntiCancerBody™, CancerVaccine™, and Tumorase™ combined to make powerful tools to prevent and treat cancer.

BioMedicure has been funded in 2005 by Dr. Yong Qian, currently the President and CEO. With the support of over 50 investors/shareholders, Dr. Qian's team was able to secure most of BioMedicure's intellectual properties, including but not limited to enriched cancer stem cells (US patents pending), whole-cell giant liposome cancer vaccines (US and international patents pending) and Tumorase™ biochemotherapy (US and international patents pending).